

Updates on E-labelling Initiatives in Malaysia 23 April 2024

Azuana Ramli, PhD
Deputy Director
National Pharmaceutical Regulatory Agency (NPRA)



1 BACKGROUND

- E-Labelling Milestones in Malaysia
- Survey on Industry Readiness: Main findings

2 E-LABELLING REQUIREMENTS IN MALAYSIA

-) Definition
- 2) Guideline
- 3) Product Scope

- 4) Implementation date
- 5) Data Format
- 6) Hosting Site

- 3 UPCOMING RESEARCH: Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries
- 4 wishlist



1 BACKGROUND

- E-Labelling Milestones in Malaysia
- Survey on Industry Readiness: Main findings

2 E-LABELLING REQUIREMENTS IN MALAYSIA

- Definition
-) Guideline
- 3) Product Scope

- 4) Implementation date
- 5) Data Format
- 6) Hosting Site

3 UPCOMING RESEARCH: Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries

4

WISHLIST



2019

Joint Industry Task Force proposed elabelling implementation in Malaysia

2022

 Issuance of directives and guidance document for e-labelling by NPRA

 Voluntary e-labelling implementation started on 1st May 2023

2024











Sharing of e-labelling initiative during industry dialogue with NPRA
 Formation of Joint Industry Task Force consist of PhAMA, MOPI and MAPS

2021

- Formation of e-Labelling Task Force consists of representatives from Ministry of Health and industrial associations
- Survey on the readiness of the industry for the e-labelling implementation is conducted

2023


- Ongoing implementation of e-labelling
- Planning for Study on Impact of Elabelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries

PhAMA: Pharmaceutical Association of Malaysia

MOPI: The Malaysian Organisation of Pharmaceutical Industries MAPS: Malaysian Association of Pharmaceutical Suppliers




MAIN RESULT OF THE SURVEY



READINESS ON E-LABELLING IMPLEMENTATION BY Q3 2022


- 20.5% ready
- 79.5% not ready due to:
 a) The current product label has been printed in a large amount
 b) Need more time to re-design label to
 - include QR code

 - Worry about variation approval time The readiness of the hosting site



WHEN DO YOU ANTICIPATE **READINESS COULD BE** ATTAINED?

- 82.3% ready to implement between 2023 2025
- 17.7% ready to implement by Q32022



WHAT IS YOUR PREFERRED **HOSTING SITE?**

■52.6% preferred NPRA

■43.6% preferred company/ 3rd party

■3.8% has no preference



1 BACKGROUND

- E-Labelling Milestones in Malaysia
- Survey on Industry Readiness: Main findings

2 E-LABELLING REQUIREMENTS IN MALAYSIA

- 1) Definition
- 2) Guideline
- 3) Product Scope

- 4) Implementation date
- 5) Data Format
- 6) Hosting Site

3) UPCOMING RESEARCH Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries

4)

WISHLIST



E-LABELLING REQUIREMENTS IN MALAYSIA

E-LABELLING DEFINITION

The provision of an approved product information that includes the

- Package Insert (PI) and/or
- Consumer Medication Information Leaflet (RiMUP)

electronically via a machine readable QR code on the outer carton/inner label of the product that links to the NPRA QUEST3+ system

VOLUNTARY IMPLEMENTATION





E-LABELLING REQUIREMENTS IN MALAYSIA

IMPLEMENTATION DATE

Voluntary starting:

1 May 2023 – 31 December 2026

IMPLEMENTATION SCOPE

Poduct Scope:
Biologic, New Drug Product & Generic Product
Containing Scheduled Poison

IMPLEMENTATION METHOD

- New product: As part of product dossier
- Existing product: Minor Variation Notification

GUIDELINE



MINISTRY OF HEALTH MALAYSIA

NATIONAL PHARMACEUTICAL REGULATORY AGENCY

GUIDELINE ON
ELECTRONIC LABELLING (E-LABELLING)
FOR PHARMACEUTICAL PRODUCTS
IN MALAYSIA

April 2023

9



E-LABELLING REQUIREMENTS IN MALAYSIA

DATA CARRIER: QR CODE

DATA FORMAT: PDF


HOSTING SITE: NPRA QUEST SYSTEM

QR CODE SCAN

COVID-19 Vaccine AstraZeneca

- The QR code may be displayed on the outer carton or inner label
- The QR code may be printed or affixed onto the outer carton/inner label using a stick-on label

NPRA QUEST SYSTEM OF THE PRODUCT:




PRODUCT INFORMATION FROM NPRA QUEST SYSTEM:

- **Product Name**
- **Registration Number**
- **Holder & Address**
- **Manufacturer & Address**
- **Importer & Address**

- Ingredient Information Packaging Information Consumer Medication **Information Leaflet (RiMUP)**
- **Product Label**
- **Package Insert**



E-LABELLING APPLICATIONS (PRODUCTS) RECEIVED



Product category:

- Biologic
- New Drug Product
- Generic Product Containing Scheduled Poison

Voluntary application by phases (PILOT):

- Phase 1: 1 May 31 July 2023
- Phase 2: 1 Aug 31 Oct 2023
- Phase 3: 1 Nov 2023 31 Jan 2024

(During PILOT, applicant will send a list of products for e-labeling application. Phase 4 is ongoing)

Procedure:

Minor Variation – Notification (MiV-N): "Do & Tell" (If the notification fulfills the requirements as per described, PRH must notify NPRA. NPRA shall acknowledge the valid notification)

- E-labelling PILOT Implementation Mechanism during Voluntary Implementation is decided by e-Labelling Task Force consists of representatives from Ministry of Health and Industrial Associations.
- Issues and problems pertaining to e-labelling will be discussed in the Task Force meeting. The meeting occurs at intervals throughout the year.



1 BACKGROUND

- E-Labelling Milestones in Malaysia
- Survey on Industry Readiness: Main findings

2 E-LABELLING REQUIREMENTS IN MALAYSIA

- 1) Definition
- 2) Guideline
- 3) Product Scope

- 4) Implementation date
- 5) Data Format
- 6) Hosting Site

- 3 UPCOMING RESEARCH: Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries
- 4 WISHLIST

UPCOMING RESEARCH:

Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries




Impact & Benefits

To assess the impact and benefits of e-labelling implementation on the public, healthcare professionals, and pharmaceutical industry



Potential

To investigate the potential for expanding the scope of e-labelling to cover other groups of products & outcome to continually improve e-labelling implementation



Asia Partnership Conference of Pharmaceutical Associations



UPCOMING RESEARCH:

Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries

Analysis of findings:

- One year after implementation (Interim analysis)
- Two years after implementation

Quantitative

Online Survey

A structured questionnaire will collect quantitative data on the perceptions, experiences, and attitudes of the public, healthcare professionals, and industries towards elabelling implementation

Methodology

Mixed Method

A combination of a questionnaire survey and semistructured interviews, which are exploratory, descriptive, or explanatory will be used

Qualitative

Focus Group

These discussions will allow for an in-depth exploration of the participants' experience, perspectives, concerns, and suggestions regarding e-labelling



1 BACKGROUND

- E-Labelling Milestones in Malaysia
- Survey on Industry Readiness: Main findings

2 E-LABELLING REQUIREMENTS IN MALAYSIA

- 1) Definition
- 2) Guideline
- 3) Product Scope

- 4) Implementation date
- 5) Data Format
- 6) Hosting Site

3 UPCOMING RESEARCH: Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries

4 wishlist



WISHLIST

Cross-Platform Compatibility:

Designing e-labeling solutions that are compatible with a wide range of devices, operating systems, and software applications enhances interoperability



Standardized Formats:

Adopting standardized formats for e-labeling data is essential for interoperability. Common formats ensure that information can be easily exchanged and understood by different systems and devices



Medication Management:

- E-labelling integration can enable healthcare providers, consumers and patients to access comprehensive medication information electronically
- This includes details such as dosage instructions, contraindications, and potential drug interactions





ACKNOWLEDGEMENT

Special thanks & gratitude to:

- Director of NPRA
- Malaysian Joint Task Force for e- labelling
- Secretariat of Malaysian Joint Task Force for e-labelling



ありがとう Arigatō